70) Löscher Mevissen et al. 1996, 1999 (cocarcinogen and 50 Hz, stab. 50.56; 1.11%) 71) Ahlbom 2000 (50 and 60 Hz; >1.25%) 72) Greenland 2000 (50 and 60 Hz; >1.25%) 73) Kheifets 2010 (50 and 60 Hz; >1.25%) 74) National Cancer Institute Electromagnetic fields and cancer, 2016 (50 and 60 Hz; >1.25%) 75) Soffritti 2016 (50.00 Hz combined with harmonic distortions 3%; stab. 50.56; >1.11%) 76) Soffritti 2016 (cocarcinogen and modulated 50.00 Hz; stab. 50.56; 1.11%) 77) Stuchly 1992 (cocarcinogen and 60 Hz, 60.75; 1.24%) 78) Cain 1993 (cocarcinogen and 60 Hz, 60.75; 1.24%) 79) Loja 2014 (125 Hz, 128; 2.3%) 80) Loja 2014 (625 Hz, 606.2; 3.1%) 81) Repacholi 1997 (modulated 900 MHz, stab. 905.9; >0.66%) 82) Wyde ME 2016 (modulated 900, stab. 905.9, >0.66%) 83) Wyde ME 2016 (modulated 1900 MHz, stab.1909.1; >0.48%) 84) Tillmann et al. 2010 (modulated 1.97 GHz; stab. 1.909; >3.20%) 85) Lerchl 2014 (modulated 1.97 GHz; stab. freq. 1.909; >3.20%) 86) Roszkowski 1980b (2.45 GHz; stab. 2.42; 1.43%) 87) Szudzinski 1982 (cocarcinogenic 2.45 GHz; stab. 2.42; 1.43%) 88) Guy 1985 (modulated 2.45 GHz; stab. 2.42; >1.43%) 89) Marcickiewicz 1986 (2,45 GHz, stab. 2.42; 1.43%) 90) Szmigielski 1982 (cocarcinogen and 2.45 GHz, stab. 2.42; 1.43%) 91) Balcer-Kubiczek 1989 (cocarcinogen 2.45 GHz, stab. 2.42; 1.43%) 92) Chou CK 1992 (modulated 2.45 GHz; stab. 2.42; 1.43%) 93) Johnson EH, 1999 (2.45 GHz; stab. 2.42; 1.43%). 94) Prausnitz and Susskind 1962 (pulsed 9270 MHz, stab. 9040 MHz; >2.54%) 95) Sperandio 2013 (780 nm, stab. 799.0; 2.4%) 96) Frigo 2009 (660 nm; stab. 674.0; 2.1%) 97) Gomes Henriques, 2014 (660 nm; stab. 674.0; 2.1%) 98) Sperandio 2013 (660 nm, stab. 674.0; 2.1%) 99) Setlow 1993 (436 nm, 449.8, 3.07%) 100) Setlow 1993 (405 nm, 399.5, 1.38%) 101) Popp 1976 (380 nm, 373.8; 1.66%) 102) Setlow 1993 (365 nm, 373.8, 2.35%) 103) Belloni 2005 (308 nm, 315.65; 2.42%) 104) De Gruijl 1993 (293 nm, 299.55, 2.19%) |